Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 6/20 | 0.45 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3306573 | 0.86 | MAOA (0.50) | CRBNMAOAMRGPRX1MAOBCA12 | |
| SCHEMBL19857573 | 0.81 | LCK (0.50) | CRBNMAOAMRGPRX1MAOBHPGD | |
| SCHEMBL28258201 | 0.79 | CRBN (0.54) | CRBNMAOAMRGPRX1MAOBERAP1 | |
| SCHEMBL3965575 | 0.79 | CRBN (0.48) | CRBNMAOAMRGPRX1MAOBCA12 | |
| SCHEMBL5003621 | 0.72 | MAOA (0.59) | MAOAMAOBCA12CA1CA2 | |
| SCHEMBL3832066 | 0.70 | PTPN1 (0.41) | MAOAPOLBCYP2C19 | |
| SCHEMBL4428324 | 0.70 | MAOB (0.58) | MAOAMAOBALDH1A1 | |
| SCHEMBL7944303 | 0.69 | POLB (0.48) | POLBCYP2C19HPGDALDH1A1LMNA | |
| SCHEMBL29784445 | 0.69 | STING1 (0.47) | CRBNMAOAMRGPRX1MAOBPOLB | |
| SCHEMBL3461283 | 0.69 | HPGD (0.53) | CRBNMRGPRX1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058425-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-11-15 | — | — | US | disclosed |
| US-8022065-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | CRBN 3335/4885MAOA 3011/4885MRGPRX1 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.